Navigation Links
Pharmacyclics Files Registration Statement for Rights Offering
Date:6/1/2009

inical development and two product candidates in pre-clinical development. It is Pharmacyclics' business strategy to establish collaborations with large pharmaceutical and biotechnology companies for the purpose of generating present and future income in exchange for adding to their product pipelines. Pharmacyclics strives to generate collaborations that allow it to retain valuable territorial rights and simultaneously fast forward the clinical development and commercialization of its products. The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations and beliefs regarding our future results or performance. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "should", "would", "project", "plan", "predict", "intend" and similar expressions are intended to identify such forward-looking statements. Our actual results could differ materially from those projected in the forward-looking statements. Additionally, you should not consider past results to be an indication of our future performance. For a discussion of the risk factors and other factors that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our annual report on Form 10-K and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking st
'/>"/>

SOURCE Pharmacyclics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
2. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
3. Pharmacyclics Secures $5.0 Million in Debt Financing
4. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
5. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
6. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
7. Pharmacyclics Announces It Received Nasdaq Notification
8. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
9. Onyx Pharmaceuticals Files Complaint Against Bayer Corporation
10. Poniard Pharmaceuticals Files Shelf Registration
11. Sinovac Biotech Ltd. Files Annual Report on Form 20-F
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Francisco, CA (PRWEB) August 20, 2014 ... Conference is being held on October 29-30 in ... perspectives from industry, academic and government researchers and clinicians ... in the space. , In the twelve years ... one hundred therapies have been introduced with pharmacogenetic information ...
(Date:8/20/2014)... GraphDB™ 6.0 from ... to the enterprise replication cluster, faster loading speeds, ... and Elasticsearch. This release happens to coincide with ... – GraphDB™ was formerly known as OWLIM. ... mature enterprise resilient RDF triplestore will also benefit ...
(Date:8/19/2014)... 2014 Cellgen Diagnostics ... to fund a corporate lab for its genetic-based ... development is a critical component in the move ... the implementation of personalized medicine – a more ... , Indiegogo contributions will support Cellgen’s intent to ...
(Date:8/19/2014)... Aug. 19, 2014 CSSi, the leader in ... announced the formation of the company,s Medical and Clinical ... addition of Dr. William E. Gannon, Jr. ... The MCAB, with Dr. Gannon,s ... therapeutic areas and set strategic goals for the advancement ...
Breaking Biology Technology:6th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3
... ... Probiotics has released a case study that provides a sustainable solution ... evidence of the effectivness of beneficial microbial applications. These results are ... Environmental Protection Agency, who recently agreed to identify and investigate ...
... ... in new product launch of Chewy Bite Line expansion to include one of a kind ... Las Vegas, ... keep up with the demand to learn more about their new products at the ASMBS ...
... As previously announced on October 24th, 2009 delSECUR sold 100% ... Ontario company, QTECH SYSTEMS INC. in exchange for 49% of shares ... QTECH,s Management Team and the appointment of a new Chief Technology Officer, ... , , ...
Cached Biology Technology:Effective Odor and Pathogen Control in Livestock Operations Revealed in New Case Study 2delSECUR CORPORATION Announces Organizational Update as QTECH SYSTEMS INC. Expands Leadership Team 2delSECUR CORPORATION Announces Organizational Update as QTECH SYSTEMS INC. Expands Leadership Team 3
(Date:8/19/2014)... engineers have devised a new implantable tissue scaffold coated ... a few weeks. When applied to bone injuries or ... form new bone that looks and behaves just like ... could offer a dramatic improvement over the current standard ... another part of the patient,s body a painful ...
(Date:8/19/2014)... neonatal abstinence syndrome (NAS) secondary to in-utero opioid ... withdrawal than others, but the underlying reasons are ... genes are turned on or off) changes have ... Boston University School of Medicine (BUSM) and Boston ... kind study to identify some of these epigenetic ...
(Date:8/19/2014)... of today,s crocodiles colonised the seas during warm phases ... new Anglo-French study which establishes a link between marine ... a period of more than 140 million years. ... the Universit de Lyon, France and formerly from the ... Nature Communications ., Today, crocodiles are ,cold-blooded, animals ...
Breaking Biology News(10 mins):Engineering new bone growth 2Engineering new bone growth 3In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2Evolution of marine crocodilians constrained by ocean temperatures 2
... the ongoing mission to train and educate scientists on ... J. Craig Venter Institute,s (JCVI) Eukaryotic Genome Annotation and ... to train 40 United States Agriculture Department (USDA) scientists ... session will focus on the use of JCVI,s eukaryotic ...
... Langone Medical Center may have discovered a new targeted ... disease, is a serious genetic disorder occurring predominantly in ... childhood. The new study entitled, "Role of calcium-independent phospholipase ... published in the Proceedings of the National Academy ...
... to the successful implantation of a fertilized human egg. ... of the implantation can all affect the outcome of ... University researcher is suggesting that prospective parents and their ... other biomechanical processes play in its success. New studies ...
Cached Biology News:JCVI program trains USDA scientists on eukaryotic genome analysis 2New potential therapeutic target discovered for genetic disorder -- Barth syndrome 2Engineering bouncing babies, 1 at a time 2
Xanthine Oxidase (Bovine Buttermilk). Monospecific by IEP. Some cross reactivity with Xanthine Oxidase of other species and tissues may occur....
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Low melting point. Ideally suited for in gel enzymatic reactions. Gelling temp. 24-28C Melting temp. 65C. EEO 0.12 Resolution 0.5-20 kb; Rnase/Dnase: none detected....
...
Biology Products: